Camurus AB (publ) (STO:CAMX)
682.00
-5.00 (-0.73%)
At close: Feb 3, 2026
Camurus AB Revenue
Camurus AB had revenue of 567.07M SEK in the quarter ending September 30, 2025, with 18.24% growth. This brings the company's revenue in the last twelve months to 2.35B, up 39.37% year-over-year. In the year 2024, Camurus AB had annual revenue of 1.87B with 8.78% growth.
Revenue (ttm)
2.35B
Revenue Growth
+39.37%
P/S Ratio
17.28
Revenue / Employee
8.41M
Employees
280
Market Cap
40.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.87B | 150.73M | 8.78% |
| Dec 31, 2023 | 1.72B | 760.51M | 79.52% |
| Dec 31, 2022 | 956.34M | 355.77M | 59.24% |
| Dec 31, 2021 | 600.57M | 264.57M | 78.74% |
| Dec 31, 2020 | 336.00M | 230.39M | 218.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioArctic AB | 1.92B |
| Saniona AB | 743.21M |
| BioInvent International AB | 244.85M |
| Hansa Biopharma AB | 178.61M |
| Genovis AB (publ.) | 117.66M |
| Egetis Therapeutics AB | 55.40M |
| Vicore Pharma Holding AB | 8.50M |
| Flerie AB | 2.80M |
Camurus AB News
- 25 days ago - Camurus's NDA Resubmission For Oclaiz Gets Accepted By FDA - Nasdaq
- 3 months ago - Camurus reports positive topline results for CAM2056, semaglutide monthly depot - PRNewsWire
- 3 months ago - Camurus AB (publ) (CAMRF) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Camurus AB (publ) 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 3 months ago - Camurus AB (FRA:7CA) Q3 2025 Earnings Call Highlights: Strong Profit Growth Amid Revenue ... - GuruFocus
- 3 months ago - Q3 2025 Camurus AB Earnings Call Transcript - GuruFocus
- 3 months ago - Camurus AB (publ) reports Q3 results - Seeking Alpha
- 8 months ago - Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients - PRNewsWire